Verve Therapeutics launched with $58.5m in series A venture capital, a high-profile CEO from academia and a big goal – what some might even call a biopharmaceutical holy grail – to prevent coronary heart disease by giving at-risk patients a single injection of a novel medicine.
Cambridge, MA-based Verve will develop gene-editing therapies that give patients genes associated with cardio-protective qualities based on the genetic discoveries...






